Merck & Co., Inc. (NYSE: MRK) is considered one of the top undervalued low volatility stocks to buy now. The first patient was dosed in the HERTHENA-Breast04 phase 3 trial, evaluating the efficacy and safety of investigational patritumab deruxtecan in patients with advanced breast cancer.

Patritumab deruxtecan is a HER3-directed antibody drug conjugate developed by Daiichi Sankyo and jointly with Merck & Co., Inc. The company focuses on delivering health solutions for animals and humans through its Pharmaceutical and Animal Health segments.

While Merck (MRK) is recognized as a reliable dividend player, certain AI stocks may offer greater upside potential. Investors seeking undervalued AI stocks can explore other options with less downside risk compared to Merck. This article was originally published on Insider Monkey’s website.

Read more at Yahoo Finance: Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial